HPV vaccination leads to rapid decline in genital warts, Australia.
Women (Health aspects)
|Publication:||Name: Reproductive Health Matters Publisher: Reproductive Health Matters Audience: General Format: Magazine/Journal Subject: Family and marriage; Health; Women's issues/gender studies Copyright: COPYRIGHT 2010 Reproductive Health Matters ISSN: 0968-8080|
|Issue:||Date: May, 2010 Source Volume: 18 Source Issue: 35|
|Topic:||Event Code: 680 Labor Distribution by Employer; 200 Management dynamics Computer Subject: Company business management|
|Geographic:||Geographic Scope: Australia Geographic Code: 8AUST Australia|
The number of young women presenting with new cases of genital
warts in Australia has declined since the introduction of the national
human papillomavirus vaccination programme. A retrospective study
examined the proportion of new patients with genital warts attending
Melbourne Sexual Health Centre from January 2004 to December 2008.
Australia has offered the quadrivalent HPV vaccine, Gardasil, free to
12-18 year old girls in schools since April 2007, and to women aged 26
and younger in general practices since July 2007. Take-up rates have
been approximately 70%. Gardasil targets HPV types 6, 11, 16, and 18.
Types 6 and 11 are associated with genital warts, and types 16 and 18
with the development of cervical cancer. A total of 36,055 new patients
attended the clinic and genital warts were diagnosed in 3,826 (10.6%).
The proportion of women under 28 years diagnosed with warts decreased by
25.1% each quarter in 2008, which was significantly different from the
1.8% increase per quarter from 2004 to 2007 (p<0.001). Women under 28
made up about 13% of patients diagnosed as having genital warts before
2008, but only 6.6% in 2008. The only other group that saw a decline in
genital warts was heterosexual men, among whom new diagnoses fell by 5%
each quarter in 2008 (p=0.031). The data suggest that a rapid and marked
reduction in genital wart incidence may be achievable through an HPV
vaccination programme targeting adolescents and young women, and
supports some benefit being conferred on heterosexual men. These results
are important for countries deciding between the bivalent vaccine that
does not protect against warts and the quadrivalent vaccine. (1,2)
(1.) Fairley CK, Hocking JS, Gurrin LC, et al. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sexually Transmitted Infections 2009;85:499-502.
(2.) Kmietowicz Z. Australian cervical cancer vaccination leads to rapid decline in genital warts. BMJ 2009; 339:b2421.
|Gale Copyright:||Copyright 2010 Gale, Cengage Learning. All rights reserved.|